This poignant editorial!https://jamanetwork.com/journals/jamaoncology/article-abstract/2854856
explains how US cancer care reimbursement is badly misaligned with clinical value, highlighting that high-value (read: effective, convenient and relatively inexpensive) radiotherapy faces year-over-year reimbursement cuts while far costlier systemic therapies only continue to rise in price. Commonsense recommendations include reducing exorbitant drug prices (e.g., via most-favored-nation pricing and expanded Medicare negotiation) and rationalizing radiotherapy payment to restore patient-centered value. | Shah, JAMA Oncol
explains how US cancer care reimbursement is badly misaligned with clinical value, highlighting that high-value (read: effective, convenient and relatively inexpensive) radiotherapy faces year-over-year reimbursement cuts while far costlier systemic therapies only continue to rise in price. Commonsense recommendations include reducing exorbitant drug prices (e.g., via most-favored-nation pricing and expanded Medicare negotiation) and rationalizing radiotherapy payment to restore patient-centered value. | Shah, JAMA Oncol